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OBJECTIVES: Atopic dermatitis (AD) is a chronic disease fre-
quent in childhood. The treatment is based on regular moistur-
izing of the skin, information to the parents on the chronic
course with recurrent ﬂares, topical anti-infectious therapy for
superinfections and colonization of the skin by staphylococcus
aureus, and topical steroids. The immuno-modulatory
macrolides (tacrolimus and pimecrolimus) represent a new alter-
native to topical steroids. To establish the importance of differ-
ent characteristics of treatment we would apply a conjoint
analysis exercise. Conjoint analysis is a technique to elicit pref-
erences toward atopic dermatitis treatment and can help plan-
ning optimal health care and guiding therapeutic decisions. The
aim of this pilot study is to establishing which characteristics
patients and caregivers consider important in atopic dermatitis
treatment to design conjoint analysis scenarious. METHODS: A
focus group identiﬁed eight treatment characteristics: Long term
adverse events, short term local adverse events, time to response,
length of response after treatment, distribution mode, pharma-
ceutical dosage form, route of administration, frequency of
applications. Caregiver (all parents) gave their opinion rating
each characteristic from 0 (not important) to 100 (very impor-
tant), moreover they could suggest other characteristics.
RESULTS: Twenty parents of children with mild or severe atopic
dermatitis were enrolled. The most important characteristic con-
sidered was: “length of response after suspension treatment”
(mean = 90), followed by “long term adverse events” (mean =
85), “short term local adverse events” (mean = 82), “distribu-
tion mode” (mean = 75), “time to response” (mean = 67). None
suggested other characteristics. In order to evaluate willingness
to pay we will add “out of pocket” costs. CONCLUSIONS: This
pilot study allowed us to identify aspects considered important
by parents for their children treatment. These results will help
us to design a Conjoint Analysis aimed at evaluating utilities and
monetary value of these aspects.
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OBJECTIVES: The aim of this study was to evaluate the impact
of atopic dermatitis (AD) on adults’ quality of life in France.
METHODS: Atopic patients coming spontaneously to their der-
matologist had to ﬁll in Quality of life questionnaires. The SF-
12 scale was administrated. It is composed of two dimensions,
a Physical Component Summary (PCS-12) and a Mental Com-
ponent Summary (MCS-12). The Dermatology Life Quality
Index (DLQI), was also administrated. RESULTS: The popula-
tion [n = 266, mean age: 33.4 years old (sd: 12)] was composed
of 34.2% of men versus 65.8% of women. The average history
of AD was 18 years (sd:13.8). Its severity was determined by the
dermatologist using the SCORAD index: 1.6% present a mild
form of atopic dermatitis, 44.1% a moderate form and 54.3%
a severe form. Mean DLQI total score was 8.8 (sd 5.5) with no
signiﬁcant difference between men, 8.6 (sd 5.3), and women, 8.8
(sd 5.6). According to the SCORAD index, mean DLQI scores
were 6.8 (sd 4.4) for group gathering “mild” and “moderate”
and 10.2 (sd 5.6) for “severe” group. Although Physical dimen-
sion (PCS-12) of SF-12 was not impaired (mean score 50.7, sd
7.3), the Mental dimension (MCS-12) was very low (mean score
39.5, sd 10.6). According to the SCORAD, MCS-12 scores were
respectively 42.8 (sd 9.8) and 36.5 (sd 10.1) for “mild or 
moderate” group and “severe” group (p < 0.0001). CONCLU-
SIONS: The quality of life of patients suffering from Atopic Der-
matitis was impaired. DLQI mean score was 8.8. This study
especially highlights the impact of AD on patient’s mental health
(MCS-12 mean score =39.5), demonstrating the importance 
of psychological interventions in addition to dermatological
management.
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OBJECTIVES: Atrial ﬁbrillation (AF) remains a major health
problem affecting 2.2 million adults in the U.S. with an estimated
cost burden of $3 billion annually. AF is also a major and pre-
ventable cause of transient ischemic attack (TIA) and stroke. The
purpose of this research was to identify demographic, clinical
and treatment factors associated with cerebrovascular co-
morbidity in AF and related medical costs. METHODS: Con-
tinuously beneﬁt-eligible patients with a “new” diagnosis of AF
(ICD-9-CM 427.3x) identiﬁed from a large administrative claims
database (N = 43 million) were identiﬁed between 1 Jan 2000–31
Dec 2001 with a variable follow-up period of £6 months.
Patients were stratiﬁed into cohorts based on initial treatment:
no-treatment (n = 40,489), warfarin (n = 6846) and other anti-
coagulants (n = 868). Clinical and demographic factors were
assessed using Cox proportional hazards regression. Medical
costs were examined using a generalized linear model with a
gamma distribution and log-link function to approximate the
non-normal distribution related to health care expenditures for
both AF and non-AF costs. RESULTS: Prior stroke was associ-
ated with a 100 fold greater risk of subsequent stroke (HR =
113.39, 95% CI = 103.22, 124.56) compared to no such history
(baseline risk = 4.7% over ~20 months of follow-up). Increased
risks also were observed with advanced age, prior TIA, left ven-
tricular dysfunction, high stroke risk (multiple co-morbidities)
and hypertension. Lower stroke risk was observed with patients
who received antithrombotic medication (HR = 0.68, 95% CI =
0.54, 0.85) as well as those receiving cardioversion or ablation.
Mean (±SE) AF-related and unrelated costs were $10,355
(±$129) and $7,661 (±$126) respectively. CONCLUSIONS:
These data are consistent with the clinical and demographic pre-
dictors of stroke/TIA. Use of antithrombotic medication appears
to confer an independent protective effect on stroke risk.
However, the costs associated with AF remain high; more aggres-
sive AF management is necessary improve clinical outcomes and
reduce medical costs.
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OBJECTIVES: The Losartan Intervention For Endpoint Reduc-
tion (LIFE) in hypertension study was a randomised, double-
blinded trial comparing effects of losartan with atenolol on
cardiovascular morbidity and death. A population of 9193
hypertensive patients with left ventricular hypertrophy (LVH) in
different countries was studied. As compared to atenolol, losar-
tan reduced the combined risk of cardiovascular morbidity and
mortality by 13% (p = 0.021), and reduced risk of stroke by
25% (p = 0.001), despite comparable blood pressure control.
Our objective was to conduct a cost-effectiveness analysis of
losartan compared with atenolol from the Dutch health care per-
spective. METHODS: Utilisation of losartan and atenolol within
the trial period and an estimation of direct medical costs of
stroke for The Netherlands were combined with estimates of
reduction in life expectancy through stroke. Medication cost and
stroke incidence during 5.5 years of patient follow-up were esti-
mated separately, adjusted for the baseline degree of LVH and
Framingham risk score. To estimate lifetime stroke costs, the
cumulative incidence of stroke was multiplied by the lifetime
direct medical costs attributable to stroke. All costs in 2004
Dutch prices were discounted at 4%, and effects at 1.5% (new
guideline). RESULTS: Prevention of stroke resulted in a gain of
5.1 discounted life years. As a consequence, losartan treatment
resulted in 0.081 life years gained per patient. Losartan reduced
stroke related cost by €946. After inclusion of study medication
cost, net cost per patient was €237 higher for losartan than
atenolol. The net cost per life year gained was €2926 which is
below the Dutch pharmacoeconomic threshold of €20,000/LYG
for accepting interventions. The corresponding probability of a
cost-effectiveness ratio below the Dutch threshold was 0.96.
CONCLUSIONS: In The Netherlands, treatment with losartan
compared with atenolol is a cost-effective intervention based on
the reduced risk of stroke observed in the LIFE trial.
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OBJECTIVES: To assess the costs effectiveness of 18-month
treatment with clopidogrel followed by aspirin versus aspirin
long life in high-risk patients with recent ischemic stroke (IS) or
transient ischemic attack (TIA) in Italy. METHODS: A Markov
model was developed to perform an indirect comparison. This
model was run with a lifetime perspective, for a cohort aged 66
(63% male). During their lifetime, patients can experience quar-
terly following events: IS, myocardial infarctions (MI), TIA,
other cardiovascular deaths, primary intracranial hemorrhages,
life threatening bleedings, or major bleedings. For the clopido-
grel arm, the events rates were taken from the recent MATCH
trial. In order to derive the aspirin arm, we applied a relative risk
increase (RRI) of 1.11 taken from the Cochrane review for car-
diovascular events, and a RRI of 1.12 from the CAPRIE trial for
hemorrhagic events. Costs were retrieved using Italian Diagno-
sis Related Group (DRG) and published sources. Annual dis-
count rate of 3% was applied for both costs and beneﬁts. Payer
perspective was used. Extensive sensitivity analyses were per-
formed. RESULTS: For a cohort of 10,000 patients, 18-month
treatment with clopidogrel instead of aspirin allow to avoid 138
recurrent IS, 28 MI, and 27 cardiovascular deaths. Clopidogrel
treatment is associated with a gain in quality adjusted life years
(QALY) of 360 years. Incremental total cost per patient (includ-
ing drugs and complications), over a remaining lifetime horizon
was €702. Incremental cost-effectiveness ratio (ICER) was
€19,500 / QALY with 57% of simulations below the acceptable
€23,000 / QALY threshold. CONCLUSIONS: In patients at high
risk of ischemic events with recent TIA or IS, 18-month treat-
ment with clopidogrel followed by continuation on aspirin was
projected to improve life expectancy, reduce risk of secondary
ischemic events and be cost-effective compared to aspirin over
patient lifetimes in Italy.
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OBJECTIVES: To compare the total costs of the Handmaster
treatment as addition to the current standard treatment of post
stroke patients with the costs of the current standard treatment
alone. METHODS: A health economic model was used to
perform a cost-consequence analysis in order to determine cost
savings resulting from the clinical effects of the Handmaster. The
patient population consisted of severe patients with a score of 4
or 5 according to the Modiﬁed Ashworth Scale and with a non-
functional upper extremity. The data sources were published lit-
erature, including the Handmaster clinical trials, Delphi panel
and ofﬁcial price/tariff lists. The primary perspective of the study
was that of the health insurer in The Netherlands. RESULTS:
The costs of treatment with the Handmaster consist of purchas-
ing and service costs. Linear depreciation was applied to the pur-
chase costs. The use of the Handmaster resulted in net cost
savings of €320 and €477, respectively at the end of year 1 and
over the 5-year period. Sensitivity analysis showed that outcomes
for the model were most sensitive to frequency and intensity of
physiotherapy. CONCLUSION: Although treatment with the
Handmaster requires an initial investment, purchase and service
costs are largely compensated by saving of costs in other com-
ponents of the regular medical care in the chronic phase post
stroke.
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OBJECTIVE: To assess the economic and epidemiologic impact
of stoke in Friuli Venezia Giulia (FVG) a region of approximately
1.2 million inhabitants in the north-eastern Italy. METHODS:
All residents of FVG are registered in to Regional Health Service
(RHS) database, which keeps tracks of the use of medical care
admissions and reimbursement purposes. We selected residents
of FVG who had during year 2000 a ﬁrst stoke hospital admis-
sion and we followed them up till death, or December 31, 2004.
(we a priory excluded people who during the period 1995–1999
had a previous CVD event). Mortality was investigated by col-
lecting information from Regional Citizen Register ﬁle. We
obtained information on medical costs from electronic databases
of prescriptions, hospitalizations, visits and diagnostic examina-
tions in FVG. Direct medical costs were quantiﬁed in the per-
spective of the RHS and are expressed in Euro 2005. RESULTS:
We enrolled 936 patients with incident stroke (mean age 77 ±
